Clinical trial
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or…
NCT00004012 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004012 |
|---|---|
| Title | Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Official title | A Phase II Trial of Oral Capecitabine in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | capecitabine |
| Start date | Dec 1, 1998 |
| Primary completion | Dec 1, 2000 |
| Completion | Dec 1, 2000 |
| First posted | May 25, 2004 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: